Brooklyn ImmunoTherapeutics

$7.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.60 (+25.24%) Today
-$0.25 (-3.15%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BTX and other stocks, options, and ETFs commission-free!

About BTX

Brooklyn ImmunoTherapeutics, Inc., also called Brooklyn ImmunoTherapeutics, is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

CEO
Ronald Guido
Employees
22
Headquarters
New York, New York
Founded
—
Market Cap
308.83M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
6.92M
High Today
$8.99
Low Today
$6.46
Open Price
$6.60
Volume
3.97M
52 Week High
$15.52
52 Week Low
$1.88

BTX Earnings

Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Apr 27, Pre-Market

You May Also Like

HARP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure